Strides Pharma Science Ltd Technical Momentum Shifts Signal Bullish Outlook

Technical Momentum and Moving Averages Signal Strengthening Uptrend

Strides Pharma Science Ltd (NSE: 688428) currently trades at ₹1,075.75, down from the previous close of ₹1,094.65. The stock’s 52-week range spans from ₹769.60 to ₹1,231.45, indicating significant volatility over the past year. The daily moving averages have turned bullish, signalling that short-term price momentum is gaining strength. This is a critical development as moving averages often act as dynamic support and resistance levels, and their bullish alignment suggests that the stock could be poised for further upward movement.

On the weekly and monthly charts, the Moving Average Convergence Divergence (MACD) indicator confirms this positive momentum. Both weekly and monthly MACD readings are bullish, reflecting sustained buying interest and momentum accumulation over these time frames. The MACD’s bullish crossover on the weekly chart is particularly encouraging, often preceding upward price moves.

Contrasting RSI and KST Indicators Highlight Caution

However, the Relative Strength Index (RSI) presents a more mixed picture. While the weekly RSI remains neutral with no clear signal, the monthly RSI is bearish, suggesting that the stock may be experiencing longer-term overbought conditions or weakening momentum. This divergence between weekly and monthly RSI readings implies that while short-term momentum is improving, longer-term strength may be under pressure.

The Know Sure Thing (KST) oscillator also reflects this duality. It is bullish on the weekly scale but mildly bearish on the monthly, reinforcing the notion of short-term optimism tempered by longer-term caution. Investors should be mindful of this divergence as it may indicate potential volatility or a consolidation phase before a decisive trend emerges.

Bollinger Bands and Dow Theory Support Mildly Bullish Outlook

Bollinger Bands on both weekly and monthly charts are mildly bullish, suggesting that price volatility is contained within an upward trending channel. This technical setup often precedes a breakout or sustained trend continuation. Meanwhile, Dow Theory analysis shows a bullish trend on the weekly chart but no clear trend on the monthly, further underscoring the mixed signals from different time horizons.

On-Balance Volume and Volume Trends Signal Divergent Sentiment

Volume-based indicators add another layer of complexity. The On-Balance Volume (OBV) is mildly bearish on the weekly chart but bullish on the monthly, indicating that while recent trading volumes may have been weak, the longer-term accumulation trend remains positive. This divergence suggests that institutional investors might still be accumulating shares despite short-term selling pressure.

Comparative Returns Highlight Strong Outperformance Versus Sensex

Strides Pharma’s price momentum is further validated by its impressive returns relative to the benchmark Sensex index. Over the past week, the stock declined by 7.92%, underperforming the Sensex’s 1.79% fall. However, over longer periods, Strides Pharma has significantly outpaced the broader market. Year-to-date, the stock has gained 19.22% compared to the Sensex’s 12.40% decline. Over one year, the stock surged 35.83% while the Sensex fell 8.26%. The three-year return is particularly striking at 523.02%, dwarfing the Sensex’s 19.35% gain. Even over five and ten years, Strides Pharma’s returns of 195.38% and 100.09% respectively, demonstrate robust long-term growth despite recent volatility.

Mojo Score Upgrade Reflects Improving Technical and Fundamental Outlook

Reflecting these developments, MarketsMOJO has upgraded Strides Pharma’s Mojo Grade from Sell to Hold as of 6 April 2026. The current Mojo Score stands at 63.0, signalling a moderate conviction in the stock’s prospects. The small-cap pharmaceutical company’s technical trend has shifted from mildly bullish to bullish, indicating a positive momentum shift that investors should monitor closely. This upgrade suggests that while the stock is not yet a strong buy, it has moved out of the sell territory and may offer selective opportunities for investors with a medium-term horizon.

Key Technical Levels and Price Action to Watch

From a price perspective, Strides Pharma’s recent trading range between ₹1,060.50 (today’s low) and ₹1,092.00 (today’s high) shows some intraday volatility but remains above the 52-week low of ₹769.60. The proximity to the 52-week high of ₹1,231.45 indicates potential upside if bullish momentum sustains. Investors should watch for a break above this high as a confirmation of renewed strength. Conversely, a sustained drop below the daily moving averages could signal a reversal or consolidation phase.

Sector and Industry Context

Operating within the Pharmaceuticals & Biotechnology sector, Strides Pharma benefits from the sector’s defensive characteristics and growth potential driven by innovation and increasing healthcare demand. The sector’s mixed technical signals mirror those seen in Strides Pharma, with many stocks experiencing short-term volatility amid longer-term bullish trends. This context supports a cautious but optimistic stance on Strides Pharma’s near-term outlook.

Investor Takeaway: Balanced Optimism with Vigilance

In summary, Strides Pharma Science Ltd is exhibiting a clear shift towards bullish momentum, supported by positive MACD readings, daily moving averages, and a recent Mojo Grade upgrade. However, mixed signals from RSI, KST, and OBV indicators counsel caution, especially given the stock’s recent short-term weakness and the divergence between weekly and monthly technicals.

Investors should consider the stock’s strong long-term outperformance relative to the Sensex and the sector’s growth potential while remaining alert to potential volatility. Monitoring key technical levels such as the 52-week high and daily moving averages will be crucial in assessing whether the bullish momentum can be sustained or if a consolidation phase is imminent.

Overall, Strides Pharma presents a compelling case for selective accumulation within a diversified portfolio, particularly for those with a medium to long-term investment horizon who can tolerate short-term fluctuations.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →